ClinicalTrials.gg
RecruitingNCT07000877NARWHALUpdated Nov 19, 2025

Nasal Decongestant to Reduce Perioperative Adverse Events in Children With Upper Respiratory Track Infections Having Anesthesia.

A Phase 4 interventional study of Decongestant nasal spray (oxymetazoline hydrochloride (0.05%)) and PLACEBO: 2.5mL of normal saline 0.9% and benzalkonium chloride 0.02% in Perioperative Respiratory Adverse Events and Anesthesia Outcomes, sponsored by Telethon Kids Institute. Recruiting at 1 site in Australia. Open to participants aged 1 Year to 8 Years. Per ClinicalTrials.gov, last updated 2025-11-19.

Sponsored by Telethon Kids Institute · Phase 4, Interventional, and Prevention

How we know

From the registry’s dates

  • Started Jun 2025; still recruiting 1 year 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
200
Allocation
Randomized
Ages
1 Year to 8 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 29 studies in Respiratory Tract Infections with a site in Australia — 5 open to participants now, 6 under way, 2 of them phase 3. Respiratory Tract Infections · Australia.

Planned enrollment
11th of 27
200 · median 189
Started
2025
with 2 others
Phase 4
3 of 29
2 open now
Registered
27th of 29
by date

Among the 29 studies in Respiratory Tract Infections with a site in Australia, this one is the 11th largest by planned enrollment of the 27 interventional ones that give a count, is one of 3 that started in 2025, is one of 3 in phase 4, and was the 27th registered.

Respiratory Tract Infections

753 studies on the registry are indexed under Respiratory Tract Infections; 112 are open to participants now.

Browse Respiratory Tract Infections studies →

Open to participants now

5 of the 29 studies in Respiratory Tract Infections with a site in Australia are open now. Recruiting first, the newest first:

All 5 open studies →

A study can be open while its sites in Australia have not opened yet or have stopped. Only those recruiting at a site in Australia →

Who these studies take

Of the 73 Respiratory Tract Infections studies recruiting now, 33 (45%) set no upper age limit and 32 (44%) stop at 75 or younger; 34 take children under 18; 23 take healthy volunteers.

This study: 1 Year to 8 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 29 studies in Respiratory Tract Infections with a site in Australia, or all of them as a file.
02

Study summary

The goal of this multicentre, double-blind, randomised controlled trial study is to learn if the use of a nasal spray to open the nasal passages and increase airflow before surgery can reduce the occurrence of perioperative respiratory adverse events in children with upper respiratory tract infection who are undergoing anesthesia.

The main questions it aims to answer are:

  • Does use of a nasal decongestant (Oxymetazoline 0.05%) reduce perioperative respiratory adverse events during emergence (when waking up from anesthesia) or in the post-anesthesia care unit in children.
  • Is it easy and acceptable to doctors, children and parents to use the nasal decongestant treatment? Researchers will compare the nasal decongestant to a placebo (a look-alike substance that contains no drug) to see if it works to reduce perioperative respiratory adverse effects.

Participants will:

  • Take a nasal decongestant or a placebo prior to surgery (just before anaesthesia is given)
  • Be monitored during and after surgery in the post-anaesthesia care unit for any perioperative respiratory adverse events.
  • Be asked about how acceptable they found the treatment.
Read the detailed description

Upper respiratory tract infections (URTI), including COVID-19 infection and the common cold, are common and frequent in children who present for elective surgery. Children with URTI are at a two-to-three-fold increased risk of perioperative respiratory adverse events (PRAE). PRAE are among the most serious and impactful consequences of paediatric anesthesia, including cardio-respiratory arrest, and therefore present a significant challenge for the pediatric anesthetist.

This two-phase, multicentre, international, double-blinded, randomised controlled trial aims to improve the safety of children with upper respiratory tract infections undergoing anesthesia by investigating the use of a nasal spray pre-operatively to reduce respiratory complications. Following informed written parental consent, 200 pediatric patients aged 1 to 8 years, undergoing general anesthesia for any surgery with current or recent URTI will be randomised to receive at the induction of anesthesia either a decongestant nasal spray or a placebo spray using the same bottle/actuator.

Monitoring and recording of PRAE (laryngospasm - closure of the vocal cords, bronchospasm - narrowing of the airways, severe and persistent coughing, airway obstruction, oxygen desaturation (\<95%) and postoperative stridor-squeaky noises when breathing) will occur throughout the procedure and in the post anesthesia care unit (PACU). We hypothesise that children who receive the nasal decongestant will be at a reduced risk of developing PRAE.

03

Conditions studied

  • Perioperative Respiratory Adverse Events
  • Anesthesia Outcomes

Keywords

  • perioperative respiratory adverse events
  • nasal decongestant
  • upper respiratory tract infection
  • Children
  • surgery
  • pediatrics
  • anesthesia
04

Who can participate

Ages eligible
1 Year to 8 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Children aged 1 to 8.99 years with a current or recent upper respiratory tract infection (\<2 weeks).
  • Undergoing interventions or surgery under general anesthesia (elective or urgent not emergency).

Exclusion criteria

Exclusion Criteria:

  • Currently taking nasal decongestants (past 24 hours) or receiving co-phenylocaine or decongestion for surgery.
  • Surgery impacting the nasal airflow, e.g. adenoidectomy, cautery of inferior turbinates.
  • Airway management with an endotracheal tube, face mask or high flow nasal oxygen.
  • Known cardiovascular, respiratory or neurological disorders giving an or above.
  • Thyroid disease.
  • Diabetes.
  • Known to the interventional products.
  • Department of Child Protection and Family Services involved in their care.
  • Planned admissions to the Paediatric Intensive Care Unit (PICU).
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 4
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
200 participants (estimated)

Study arms

  • Active comparator
    Decongestant nasal spray (oxymetazoline hydrochloride 0.05%)

    Decongestant nasal spray, oxymetazoline (0.05%). Specific: 2.5mL of oxymetazoline 0.05% dispensed into amber brown 15ml bottles with pump and actuator attached. Children aged 1 to 5.99 years will receive 1 spray of either the nasal decongestant or placebo into each nostril, while children aged 6 years and above will receive 2 spays per nostril. Administration will be recorded on the standard patient's Medication Chart.

    Drug: Decongestant nasal spray (oxymetazoline hydrochloride (0.05%))

  • Placebo comparator
    Placebo Comparator : Placebo spray (control group)

    Matched Placebo spray. Specific: 2.5mL of normal saline 0.9% and benzalkonium chloride 0.02% dispensed into amber brown 15ml bottles with pump and actuator attached. Dose: children aged 1 to 5.99 years will receive 1 spray of either the nasal decongestant or placebo into each nostril, while children aged 6 years and above will receive 2 spays per nostril. Administration will be recorded on the standard patient's Medication Chart.

    Drug: PLACEBO: 2.5mL of normal saline 0.9% and benzalkonium chloride 0.02%

Interventions

  • DrugDecongestant nasal spray (oxymetazoline hydrochloride (0.05%))

    Decongestant nasal spray containing active ingredient.

  • DrugPLACEBO: 2.5mL of normal saline 0.9% and benzalkonium chloride 0.02%

    Control nasal spray containing no active ingredient.

06

What researchers measure

Primary outcomes

  1. Incidence of perioperative respiratory adverse event (PRAE) following the delivery of a nasal decongestant (Oxymetazoline 0.05%) or placebo prior to surgery under anesthesia in children with upper respiratory tract infection

    PRAE will be defined as laryngospasm, bronchospasm, severe persistant coughing, hypoxaemia (\<95% for at least 10 seconds), airway obstruction, stridor or pulmonary aspiration. Incidence will be assessed by the clinician caring for the patient. Incidence is binary - yes if PRAE occured, no otherwise.

    Time frame: On day of surgery: Perioperative period. PRAE will be assessed if it occurs anywhere along the perioperative pathway between the beginning of the patient's emergence from anesthesia and their discharge from the post-anesthetic care unit (PACU)

Secondary outcomes

  1. Assess the incidence of severe PRAE during emergence or in PACU in children who received the decongestant spray compared to the control group.

    Severe PRAE is defined as laryngospasm or bronchospasm, as assessed by the clinician caring for the patient.

    Time frame: Day of surgery: Perioperative period. Severe PRAE will be assessed if it occurs anywhere along the perioperative pathway between the beginning of the patient's emergence from anesthesia and their discharge from the post-anesthetic care unit (PACU)

  2. Assess the incidence of minor PRAE during emergence or in PACU inchildren who recieved the decongestant spray compared to the control group.

    Minor PRAE is defined as severe coughing, desaturation \<95% for at least 10 seconds, airway obstruction, stridor or pulmonary aspiration, as assessed by the clinician caring for the patient.

    Time frame: Day of surgery: Perioperative period. Minor PRAE will be assessed if it occurs anywhere along the perioperative pathway between the beginning of the patient's emergence from anesthesia and their discharge from the post-anesthetic care unit (PACU)

  3. Evaluate the acceptability of nasal decongestant use at the induction of anesthesia in children with upper respiratory tract infection aged 4 and older and their parents/guardians

    Children aged 4 and over and their parents/guardians will be asked to rate the acceptibility of the intervention using a 5-point Likert scale (1 = completely unacceptable; 5 = completely acceptable).

    Time frame: Patients and parents/guardians will be asked to rate the intervention post-operatively, prior to their discharge from hospital.

  4. Evaluate the acceptability of nasal decongestant use at the induction of anesthesia by the treating anaesthetist

    Treating anaesthetists will be asked to rate the acceptibility of the intervention on a 5-point Likert scale (1 = completely unacceptable; 5 = completely acceptable)

    Time frame: Treating anaesthetists will be asked to rate the intervention immediately after the administration of the interventional product.

  5. Incidence of any potential adverse effects related to the administration of the nasal decongestant/placebo

    Any potential adverse effects will be recorded as per the study doctor and the clinical team caring for the patient.

    Time frame: Any potential adverse effects will be assessed from the administration of the interventional product until the patient's discharge from hospital.

  6. Assessment of the successful administration of the interventional product in children

    This will be based upon the clinical judgement of the treating anesthesia clinician.

    Time frame: Successful administration of the interventional product will be assessed by the study team at induction of anesthesia, immediately following the administration or attempted administration of the nasal decongestant or placebo.

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2025 (actual). Primary completion is estimated for May 2028, 35 months after the start.

Of 29 phase 4 interventional studies under Respiratory Tract Infections, half reached primary completion within 11 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 51. This study's planned 35 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
May 13, 2025
First posted
Jun 3, 2025
StartActual
Jun 25, 2025
Primary completionEst.
May 30, 2028
CompletionEst.
May 30, 2028
Last update
Nov 19, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 19, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07000877
Lead sponsor
Telethon Kids Institute
Collaborators
Child and Adolescent Health Service - Perth, University of Sao Paulo General Hospital, Rigshospitalet, Denmark
Responsible party
Sponsor
First posted
Jun 3, 2025
Start date
Jun 25, 2025
Primary completion
May 30, 2028 (estimated)
Completion
May 30, 2028 (estimated)
Last update
Nov 19, 2025

Study contacts

Britta S. von Ungern-Sternberg, MD PHD
Contact
britta.regli-vonungern@health.wa.gov.au
+618 6456 4806

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion